Blue Finessence
Blue Finessence
  • Home
  • About Us
  • Services
    • Our Services
    • Company Formation in Europe
  • News
    • Internal News
    • General news
  • Contact
  • Your cart is currently empty.

    Sub Total: $ 0,00 View cartCheckout

Texas Sues Tylenol Maker Over Allegedly Omitting Evidence Of Autism Link From Marketing

Home / Finance / Texas Sues Tylenol Maker Over Allegedly Omitting Evidence Of Autism Link From Marketing
Texas Sues Tylenol Maker Over Allegedly Omitting Evidence Of Autism Link From Marketing
  • October 28, 2025
  • test
  • 71 Views

Texas Sues Tylenol Maker Over Allegedly Omitting Evidence Of Autism Link From Marketing

Texas Sues Tylenol Maker Over Allegedly Omitting Evidence Of Autism Link From Marketing

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Tylenol’s current and former manufacturer intentionally withheld evidence of a link between the drug and autism, a new lawsuit alleges.

Tylenol lines the shelves of a store in Brandon, Miss., on Sept. 24, 2025. John Fredricks/The Epoch Times

“Defendants had the authority and the duty to change the warning labels of Tylenol products based on the significant scientific evidence, but chose not to,” stated the suit, filed by Texas Attorney General Ken Paxton in a court in Texas on Oct. 28.

Some studies have found that babies born to women who took Tylenol or another form of acetaminophen have a higher risk of autism spectrum disorder (ASD) or attention-deficit hyperactivity disorder (ADHD). That includes a 2019 study published by JAMA Psychiatry.

That and other papers meant pregnant women should be cautioned against indiscriminately using acetaminophen, more than 90 researchers said in a 2021 statement.

Johnson & Johnson, which for decades manufactured Tylenol, decided against warning consumers and instead promoted Tylenol as safe, including by pointing to a website called BabyCenter that it actually owned, the suit stated.

In 2022, Johnson & Johnson spun off the manufacturing unit into a new company, Kenvue.

“This was designed to shield Johnson & Johnson’s assets from claimants who successfully sue because children develop ASD and/or ADHD after their mothers ingested Tylenol during pregnancy,” Paxton said in the suit.

Oral arguments in an appeal in one of the cases are scheduled for November.

The current label for Tylenol does not contain any warnings about autism or ADHD, although federal officials recently said they would be updating the label and told doctors that there is evidence indicating there may be a link.

Johnson & Johnson did not respond to a request for comment regarding the litigation.

A top Johnson & Johnson scientist said in an internal email in 2018, obtained by The Epoch Times—concerning more research about a possible association between Tylenol and neurodevelopmental issues—that “the weight of evidence is starting to feel heavy to me.”

“We will vigorously defend ourselves against these claims and respond per the legal process. We stand firmly with the global medical community that acknowledges the safety of acetaminophen and believe we will continue to be successful in litigation as these claims lack legal merit and scientific support,” a spokesperson for Kenvue told The Epoch Times in an email.

“We also encourage expecting mothers to speak to their health professional before taking any over-the-counter medication, including acetaminophen, as indicated on our product label for Tylenol.”

Paxton is requesting that the court block Johnson & Johnson and Kenvue from deceptively advertising Tylenol in Texas, order the companies to destroy marketing materials that portray Tylenol as safe for pregnant women, and fine the companies $10,000 per violation of the state law prohibiting deceptive promotions.

“Big Pharma betrayed America by profiting off of pain and pushing pills regardless of the risks. These corporations lied for decades, knowingly endangering millions to line their pockets,” Paxton said in a statement.

“Additionally, seeing that the day of reckoning was coming, Johnson & Johnson attempted to escape responsibility by illegally offloading their liability onto a different company. By holding Big Pharma accountable for poisoning our people, we will help Make America Healthy Again.”

Tyler Durden
Tue, 10/28/2025 – 14:25

Tyler DurdenSource

Share:

Previus Post
Hegseth Announces
Next Post
“Our Business

Leave a comment

Cancel reply

Recent Posts

  • Independent assessment to support establishment of a Future Entity
  • Predisposizione, da parte dell’Agenzia delle entrate, delle bozze dei registri IVA, delle liquidazioni periodiche dell’IVA e della dichiarazione annuale dell’IVA di cui all’articolo 4 del decreto legislativo 5 agosto 2015, n. 127. Ulteriore estensione del periodo sperimentale stabilito con il provvedimento del Direttore dell’Agenzia delle entrate n. 183994 dell’8 luglio 2021 (provvedimento)
  • Istituzione delle causali contributo per il versamento, tramite modello F24, dei contributi all’INPS da destinare ad Enti Bilaterali (risoluzione n. 5)
  • Deadline for challenging your business rates valuation
  • Targeted financial support for aspiring social workers

Recent Comments

  1. validtheme on Digital Camera

Archives

  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025

Categories

  • Finance
  • internal news
  • Italy
  • Uncategorized
  • United Kingdom

Recent Posts

  • Independent assessment to support establishment of a Future Entity
    09 March, 2026Independent assessment to support
  • Predisposizione, da parte dell’Agenzia delle entrate, delle bozze dei registri IVA, delle liquidazioni periodiche dell’IVA e della dichiarazione annuale dell’IVA di cui all’articolo 4 del decreto legislativo 5 agosto 2015, n. 127. Ulteriore estensione del periodo sperimentale stabilito con il provvedimento del Direttore dell’Agenzia delle entrate n. 183994 dell’8 luglio 2021 (provvedimento)
    09 March, 2026Predisposizione, da parte dell’Agenzia
  • 09 March, 2026Istituzione delle causali contributo
  • Deadline for challenging your business rates valuation
    09 March, 2026Deadline for challenging your

Tags

Blue%20Finessence

Excellence decisively nay man yet impression for contrasted remarkably. There spoke happy for you are out. Fertile how old address did showing.

Contact Info

  • Address:CEO Blue FinEssence Ltd Piccadilly Circus 126 London
  • Email:director@bluefinessence.com
  • Phone:004407784915057

Copyright 2024 Bluefinessence. All Rights Reserved by Bluefinessence

  • About Us
  • Our Services